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144 Poster Session IIcompared to the minor-mismatched pair. Conversely, when WT
HSC and TCs were transplanted into myeloablated and non-mye-
loablated mMTmice, BC engraftment was readily established, mak-
ing a direct anti-BC cytotoxicity unlikely as the sole cause of the BC
inhibition. FACS analysis of the bone marrow revealed a shift of the
developmental BC stages of from mature to immature stages in B
lymphopenic mice. While GVHD affected mice that received
WT grafts displayed a lower proportion of IgM expressing BCs, re-
cipients of mMTTCs showed a complete block in BC development
with an absent switch to the expression of IgM. In conclusion, TCs
from mMT mice can block BC maturation when transferred into
WTmice, an observation which shows that mature TC are capable
of interfering with BC regeneration post transplantation. This
HCT model using WT and mMT B6 mice provides a powerful
tool for studying the role of TC function in the process of donor
BC development post-HCT.396
B LYMPHOCYTE RECONSTITUTION FOLLOWING ALLOGENEIC STEM
CELL TRANSPLANTATION FOR HAEMATOLOGICAL DISORDERS: CORRE-
LATION WITH PRE- AND POST-TRANSPLANT FACTORS
Richardson, D.S., Hodges, E., Mani, A., Hurlock, C., Newman, J.,
McKeag, N., Hill, K., Orchard, K.H. Southampton University Hospitals,
Southampton, Hampshire, United Kingdom.
We have performed a detailed analysis of the kinetics of B cell re-
constitution in patients who have undergone allogeneic stem cell
transplantation for haematological disorders. Whole blood samples
from 76 patients were analysed using monoclonal antibodies di-
rected against CD19, CD27 and IgD by multicolour flow cytome-
try. Total (CD191), naive (IgD1CD27-), IgD memory
(IgD1CD271) and class switched memory (IgD-CD271) B cell
populations were identified. Indications for transplantation were
haematological malignancy (n 5 74) and aplastic anaemia (n 5 2).
The stem cell source was from an unrelated donor in 29 cases or re-
lated/sibling donor in 47 cases. 39 patients received reduced inten-
sity and 37 full intensity transplant conditioning regimens. In vivo
T-cell depletion with Campath 1H was used for all patients with
a matched unrelated donor and those receiving reduced intensity
conditioning. The majority of patients (n5 57) have retained a pre-
dominantly naive B cell phenotype at 2 to 48 months (median 18.7
months). 7 patients have a normal percentage of memory B lympho-
cytes with a low percentage of class-switched B cells. 7 patients cur-
rently have a normal percentage of class-switched B cells. 8 patients
achieved normal class-switched B cell numbers but returned to a na-
ive B cell phenotype. In one patient this preceded relapse of under-
lying leukaemia and in two others was consequent on treatment
with chemotherapy or corticosteroid. Only one patient who re-
quired treatment with additional immunosuppressive therapy,
post transplant, subsequently achieved a normal percentage of
class-switched B cells. The use of Campath 1H, stem cell source
(marrow or peripheral blood), donor type (unrelated or related),
use of full or reduced intensity conditioning or the administration
of donor lymphocyte infusions post-transplant were not predictive
of development of a normal percentage of class-switched B lympho-
cytes. B cell immune reconstitution phenotype does not appear to
correlate with the incidence of chronic GvHD or in this cohort of
patients with current disease status. The timing of development of
a normal percentage of class-switched B cells cannot be reliably pre-
dicted in this patient population.397
MINIMAL RESIDUAL DISEASE AND CHIMERISM IN CML PATIENTS RE-
CEIVING ALLOGENEIC TRANSPLANTS AFTER MYELOABLATIVE OR RE-
DUCED CONDITIONING
Uzunel, M., Mattsson, J., Hauzenberger, D., Ringden, O. Karolinska
University Hospital, Stockholm, Sweden.
It is not known whether reduced conditioning is associated with
prolonged period of detectable disease after SCT in patients withCML. We have therefore compared BCR-ABL transcript levels in
patients receiving a conventional myeloablative conditioning with
those receiving reduced conditioning. We also made chimerism
studies in both patient groups.
Myeloablative Conditioning (MYC): 31 patients, 19 matched
unrelated donors (MUD) and 12 sibling donors (Sib). Median age
was 42 years (10–61). Conditioning with Bu1Cy (n 5 31). Twenty
of theMUDpatients were also given ATG. Seven patients have died
(6 GVHD, 1 Relapse). Median follow-up time: 56 months (10–99).
Reduced Intensity Conditioning (RIC): 24 patients, 13 MUD
and 11 Sib. Median age was 55 years (11–64). Conditioning with
Flu1Bu1ATG. Seven patients have died (3 Relapses, 1 GVHD,
3 other reasons). Median follow-up time: 43 months (18–100). Re-
sults: There was no statistical significant difference in overall sur-
vival and relapse free survival between both groups. 5/29 patients
in the MYC group relapsed as compared to 7/23 patients in the
RIC group. Only one patient in the RIC group rejected the graft.
The incidence of severe acute GVHD was significantly higher in
the MYC group (48%) as compared to the RIC group (13%), p 5
0.004. Interestingly, the incidence of chronic GVHD was slightly
higher in the RIC group, 51% vs. 37% (p 5 0.11).
During the first 3 months, MRD levels in the RIC group was in
median one log of magnitude higher than in the MYC group (p 5
0.01). After that, no significant differences in the MRD incidence
and MRD level were found between the groups.
Median time to complete donor T-cell chimerism was 34 days
(14–285) in the MYC group as compared to 60 days (24–245) in
the RIC group (p5 0.04). Also, complete myeloid cell engraftment
was delayed in the RIC group, median 44 days (14–165) as
compared to 25 days (14–270) in the MYC group (p 5 0.02).
Conclusion: Despite higher BCR-ABL levels during the early
post-transplant period and higher incidence of mixed chimerism,
nonmyeloablative transplantation for CML patients may induce
molecular remission in the majority of the patients.398
TRANSCRIPTIONAL ANALYSIS OF CD41 T CELLS FROM TOLERANT PA-
TIENTS AND NORMAL CONTROLS. GENE EXPRESSION IN PATIENTS DIF-
FERS FROM NORMAL CONTROLS
Tabellini, L., Haeusermann, P., Bumgarner, T.E., Flowers, M.E.,
Grogan, B.M., Martin, P.J., Hansen, J.A. Fred Hutchinson Cancer Re-
search Center, Seattle, WA.
GVHD is a major complication of hematopoietic cells transplan-
tation (HCT). Immune suppression therapy (IST) is administered
for prophylaxis and treatment of GVHD. Chronic GVHD usually
occurs within 3 to 24 months from HCT, and requires on average
24 months of IST before disease becomes quiescent and IST can
be withdrawn. We have characterized gene expression changes in
CD41 T cells of HCT patients with resolved GVHD to see if dis-
tinct translational changes are associated with immunological toler-
ance. The study included 10 patients who had been off all IST for at
least 4 months (median 9 months; range 4–38 months) without ev-
idence of active cGVHD. Six achieved tolerance within the first year
(‘‘early’’ tolerance). Four developed cGVHD within the first year
but were subsequently withdrawn from all IST between 6–38
months post-HCT (‘‘late’’ tolerance). Blood samples from early tol-
erants were obtained between 12–29 (median 12) months, from the
late tolerants were obtained between 38–52 (median 45) months
post-HCT. CD41 T cells were isolated from cryopreserved
PBMC. RNA was hybridized on HumanRef-8 v2 BeadChips,
scanned and normalized using BeadStudio (Illumina), gene expres-
sion in CD41T cells from the 10 tolerant patients was compared to
gene expression in CD41 T cells from 19 normal controls using
a false positive discovery rate of \10. Expression levels differed
for 266 genes in tolerant patients (124 upregulated and 142 down-
regulated) compared to normal controls; and 189 of these genes
could be assigned to a functional class. Selected examples are:
DNA repair (6 genes); cell cycle regulation (18 genes); RNA tran-
scription (9 genes); protein translation (8 genes); ubiquitin cycle
(6 genes); glycolysis and aerobic respiration pathways (5 genes);
and lipid metabolism (3 genes). FAS gene showed relatively strong
upregulation in all patients. Although the numbers of early and late
Poster Session II 145tolerants was small, there was a trend for downregulation of genes
associated with T cell activation and up regulation of genes associ-
ated with apoptosis in the former. These preliminary data demon-
strate significant differences in gene transcription in CD41 T
cells in patients presumed to have achieved immunological toler-
ance compared to control CD41 T cells suggesting that tolerance
in HCT patients is not simply attributable to clonal deletion but
rather that anergy in these cases is an active process maintained
by measurable alterations in transcriptional and possibly metabolic
activity.399
EXAMINING HUMAN TCR CDR3 DIVERSITY DURING LYMPHOPENIA
Memon, S.A., Gress, R.E., Hakim, F.T. National Cancer Institute, NIH,
Bethesda, MD.
Investigations of T cell receptor (TCR) repertoire diversity have
contributed to our current understanding of the post-transplant ef-
fects on T cell populations of antigen-driven peripheral expansion
and thymic-dependent immune reconstitution. Spectratyping, the
RT-PCR based assessment of variation in the lengths of the com-
plementarity determining region 3 (CDR3) of the TCR BV fami-
lies, has been widely used to define oligoclonal, skewed and
polyclonal Gaussian-like repertoire diversity. The limited levels of
circulating T cells following transplantation have, however, limited
the use of this technique on clinically available samples.We here re-
port on a sensitive, reproducible and rapid method that reliably ob-
tains TCR BV spectratypes from 100,000 T cells. Key technical
elements include consistent standardization at 100,000 CD4 or
CD8 T cells for all assays, use of carriers such as glycogen and
tRNA to maximize recovery during RNA purification, detection
of DNA fragment length on sensitive DNA sequencing platforms
and broad evaluation of as many as 13 peak locations for assessment
of spectratype variation. We have determined that fewer than
100,000 T cells can result in increased random variation in spectra-
type, while a 10-fold or greater increase in cells does not alter the
proportional representation of peaks in a spectratype. The use of
small cell numbers in our technique permits evaluation of repertoire
diversity in limited clinical samples available during lymphopenia,
and supports the separation of samples into T subsets. CD41 and
CD81 populations were found to undergo distinct patterns of rep-
ertoire recovery following transplant; analysis of unsorted T cells
masks these distinctions. Further, we have sorted CD8 T cells
into naı¨ve, CD81 memory and CD81 activated cells, compared
T subset spectratypes with that of the total CD8 population, and
demonstrated recovery of repertoire diversity in naı¨ve and memory
CD8 populations that were obscured by persistent oligoclonal rep-
ertoires in effector populations. Finally, by analyzing divergence of
each patient BV family spectratype from a standard, generated by
averaging the proportional peak distributions in spectratypes from
normal adult donors, we have established a sensitive global diversity
assay to detect changes within patient repertoires. Utilizing these
techniques will broaden the utility and enhance the sensitivity of
analyses of TCR repertoire diversity.400
RESIDENT HUMAN MYELOID DENDRITIC CELL ACTIVATION AND LOCAL
ALLOGENEIC T CELL RESPONSES IN THE BONE MARROW OF HUMAN-
IZED NOD/SCID MICE
Hart, D.N.J.1, Vuckovic, S.1, Alison, R.M.1, Kato, M.1, Khalil, D.1,
Fadilah, S.A.W.2, Rodwell, R.3. 1MaterMedical Research Institute, Bris-
bane, Queensland, Australia; 2Faculty ofMedicine, HUKM,Kuala Lum-
pur, Malaysia; 3Mater Hospital, Brisbane, Queensland, Australia.
Resident human dendritic cells (DC) in vascularized lymphoid
organs such as bone marrow (BM) and spleen (SP) may contribute
significant T cell responses to the overall systemic immune re-
sponses. To address this possibility in vivo, we developed humanized
(hu)NOD/SCID mice, which contain human resident DC in the
BM and SP derived from engrafted cord blood CD341 cells.When huNOD/SCIDmice were injected with polyinosinic:polycy-
tidylic acid [poly(I:C)], activation of the resident human myeloid
(M)DC occurred concurrently, in the BM and SP, within 2–8 h of
injection. Poly(I:C) activated human MDC in the BM and SP in-
creased the proportions of CD861MDC and their production of
IL-6, IL-10 and IL-12. The presence of activated resident human
MDC, prior to human allogeneic naı¨ve T cell transplantation was
associated with subsequent donor T cell activation, proliferation
and effector cell generation in the BM and SP of recipient mice.
However, the division kinetics of donor T cells appeared to be tis-
sue-specific, with those in the BM undergoing six to eight divisions,
whereas in the SP, the majority of donor T cells that entered a first
division did not undergo subsequent division.Thus, human resident
MDC in both BM and SP undergo rapid activation in response to
systemic activator and contribute, according to their location, to
distinctly different division kinetics of the locally recruited donor
T cells. The findings in this humanized mouse model highlight
the contribution of activated resident MDC in controlling local do-
nor T cell responses and have direct application to investigations on
the contribution of conditioning and DC activation to the patho-
genesis of acute graft versus host disease following clinical alloge-
neic haematopoietic stem cell transplantation.401
Melan-A SPECIFIC UMBILICAL CORD BLOOD (UCB) T CELLS SHOW EV-
IDENCE OF CYTOLYTIC FUNCTION AND PERSISTENCE IN THE UCB PE-
DIATRIC TRANSPLANT RECIPIENT
Merindol, N.K.1, Caty, M.1, Gimmig, S.2, Duval, M.3,
Champagne, M.3, Soudeyns, H.1. 1CHU Sainte Justine, Montreal,
QC, Canada; 2CHUM Saint Luc, Montreal, QC, Canada; 3CHU
Sainte Justine, Montreal, QC, Canada.
UCB has been used successfully as a source of progenitor cells to
treat a variety of haematological and immune disorders in children.
Donor-derived T cells play a key role in antitumoral and antiviral
immunity and contribute to the survival of the graft recipient.
Here we studied the diversity, fate and antitumoral function of
UCB-derived T cells and characterized their persistence and possi-
ble role in the pediatric graft recipient. Naı¨ve CD81T cells specific
for the Melan-A26–35 peptide (ELAGIGILTV) were isolated from
UCB and UCB transplant recipients at 1, 3, and 6 months post-
transplant using Melan-A26–35-HLA-A2 tetramers and cell sorting,
and were cultured in the presence of IL-2, IL-7, PHA and/or
cognate peptide. Melan-A-specific cytotoxicity was tested in
51Cr-release assays, and the clonal diversity of the pre-immune
Melan-A-specific repertoire was determined by sequencing of the
T cell receptor (TCR) b chain CDR3 region.
On the one hand, 12 UCB units were analysed for the diversity of
their Melan-A specific pre-immune T cell repertoire. Using pep-
tide-MHC tetramers, Melan-A-specific CD81 T cells were de-
tected at a median frequency of 0.11% in 83.3% of UCB samples
tested. Following in vitro stimulation with Melan-A peptide, all
UCB samples tested (n5 12) remained Melan-A tetramer-positive,
themedian frequency of tetramer-positive cells in CD81T cells was
increased significantly (p\0.0001), T cell microcultures exhibited
Melan-A-specific cytolytic activity, and the TCR beta chain reper-
toire showed evidence of oligoclonality consistent with antigen-
driven expansion.
On the other hand, 14 UCB recipients were enrolled in our pro-
spective study group. When samples from UCB units used for UCB
transplant were examined, Melan-A-tetramer-positive T cells were
detected in CD81 T cells (median frequency of 1.0%). These cells
proliferated in the presence of Melan-A peptide (4 of 6 cases) and
showed cognate cytolytic activity (2 of 6 cases). Tetramer-positive
cells were detected in 2 UCB transplant recipients as early as 1
month post-transplant.
This study will allow us to better understand the fate of the pre-
immune T cell repertoire in UCB pediatric transplant recipients
and will inform on mechanisms involved in graft versus host disease
and the graft versus leukaemia effect.
